.png){kind=icon}
.png){kind=icon}
Return
Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023–2025
.png){kind=icon}
OA
AI
L
O
S
J
DOI：10.1016/j.vaccine.2026.128896.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Most AEs following Arexvy® and Abrysvo® vaccination were non-serious and consistent with expected vaccine reactogenicity. • Administration of extra dose of RSV vaccine was commonly reported in all ages, for all age groups analyzed (50–74 and ≥ 75 years), and across all vaccination settings. • Although not recommended for use during the reporting period, 4.2% (n = 244) of Arexvy® reports were from individuals younger than 50 years old, and 6.6% (n = 375) were reports of exposure during pregnancy.
Keywords:
RSV vaccine
Safety
Administration errors
Post-marketing
Pregnancy
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.5
Papers:
2.1K
Citations:
4.7W
Organization
No organization information available
Cited Papers